Neoadjuvant chemoradiotherapy followed by resection for esophageal cancer: clinical outcomes with the ‘CROSS-regimen’ in daily practice

Summary Background and objectives Since the first results of the Dutch randomized CROSS-trial, neoadjuvant chemoradiotherapy (CRT) using carboplatin and paclitaxel followed by resection for primary resectable nonmetastatic esophageal cancer (EC) has been implemented as standard curative treatment in...

Full description

Saved in:

Bibliographic Details
Published in:	Diseases of the esophagus Vol. 35; no. 4
Main Authors:	Cloos-v.Balen, Marissa, Portier, Edmée S H, Fiocco, Marta, Hartgrink, Henk H, Langers, Alexandra M J, Neelis, Karen J, Lips, Irene M, Peters, Femke P, Slingerland, Marije
Format:	Journal Article
Language:	English
Published:	United States Oxford University Press 19-04-2022
Subjects:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carboplatin Chemoradiotherapy Esophageal Neoplasms - pathology Humans Neoadjuvant Therapy - methods Original Paclitaxel Retrospective Studies adverse effects chemoradiotherapy esophagectomy neoadjuvant therapy esophageal neoplasms
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Summary Background and objectives Since the first results of the Dutch randomized CROSS-trial, neoadjuvant chemoradiotherapy (CRT) using carboplatin and paclitaxel followed by resection for primary resectable nonmetastatic esophageal cancer (EC) has been implemented as standard curative treatment in the Netherlands. The purpose of this retrospective study is to evaluate the clinical outcomes of this treatment in daily practice in a large academic hospital. Methods Medical records of patients treated for primary resectable nonmetastatic EC between May 2010 and December 2015 at our institution were reviewed. Treatment consisted of five weekly courses of carboplatin (area under the curve 2) and paclitaxel (50 mg/m2) with concurrent external beam radiotherapy (23 fractions of 1.8 Gy), followed by transthoracic or transhiatal resection. Data on survival, progression, acute and late toxicity were recorded. Results A total of 145 patients were included. Median follow-up was 43 months. Median overall survival (OS) and progression-free survival (PFS) were 35 (95% confidence interval [CI] 29.8–40.2) and 30 (95% CI 19.7–40.3) months, respectively, with corresponding 3-year OS and PFS of 49.6% (95% CI 40.4–58.8) and 45.6% (95% CI 36.6–54.6). Acute toxicity grade ≥3 was observed in 25.5% of patients. Late adverse events grade ≥3 were seen in 24.8%, mostly esophageal stenosis. Conclusion Neoadjuvant CRT followed by resection for primary resectable nonmetastatic EC in daily practice results in a 3-year OS of 49.6% (95% CI 40.4–58.8) and PFS of 45.6% (95% CI 36.6–54.6), compared with 58% (51–65%) and 51% (43–58%) within the CROSS-trial. The slightly poorer survival in our daily practice group might be due to the presence of less favorable patient and tumor characteristics in daily practice, as is to be expected in daily practice. Toxicity was comparable with that in the CROSS-trial and considered acceptable.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1120-8694 1442-2050
DOI:	10.1093/dote/doab068